UK Extends Recognition Of EU Batch Testing Pending Review
Industry Welcomes ‘Pragmatic’ Move
Executive Summary
Having to set up duplicate testing facilities in the EU and the UK is an expensive business, so pharmaceutical companies are relieved that the UK is giving them some extra breathing space.
You may also be interested in...
Brexit: UK Industry Body Slams 'Ill Considered' Guidance On Batch Testing
The UK BioIndustry Association says the updated guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
UK In Major Move To Boost Commercial Clinical Trials & Improve Life Sciences Environment
The publication of two major reports has led the UK government to announce a £650m “Life Sci for Growth” package to bolster the life sciences sector.
UK Reveals Seven Partners Whose New Drug Approvals It Will Recognize
The UK regulator, the MHRA, says that while it will recognize drug approvals granted in the EU and a selection of other countries, it will remain a “sovereign regulator” with the ability to reject applications if they don’t meet its standards.